Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash & Current Investments (2016 - 2025)

Cytokinetics (CYTK) has disclosed Cash & Current Investments for 16 consecutive years, with $882.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments changed N/A to $882.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $882.2 million, a N/A change, with the full-year FY2025 number at $882.2 million, changed N/A from a year prior.
  • Cash & Current Investments was $882.2 million for Q4 2025 at Cytokinetics, up from $737.1 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $1.1 billion in Q2 2024 to a low of $350.3 million in Q2 2021.
  • A 5-year average of $679.7 million and a median of $619.3 million in 2024 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: surged 92.83% in 2021, then plummeted 37.81% in 2023.
  • Cytokinetics' Cash & Current Investments stood at $471.6 million in 2021, then surged by 66.27% to $784.2 million in 2022, then dropped by 21.55% to $615.2 million in 2023, then soared by 64.51% to $1.0 billion in 2024, then dropped by 12.83% to $882.2 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Cash & Current Investments are $882.2 million (Q4 2025), $737.1 million (Q3 2025), and $783.2 million (Q2 2025).